Results 21 to 30 of about 380,241 (288)
Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer [PDF]
Annals of Translational Medicine, 2021 In recent years, immunotherapy has achieved notable success in cancer treatment. Indeed, the novel immune checkpoint lymphocyte activation gene-3 (LAG3) has shown promising therapeutic efficacy in non-small cell lung cancer. However, it is unclear about the role of LAG3 in immunotherapy and survival in small cell lung cancer (SCLC).The expression of ...Sun, Hui, Dai, Jiawei, Zhao, Lishu, Zhu, Jun, Wang, Hao, Chen, Peixin, Lu, Hui, Chen, Qiankun, Zhang, Zhemin +8 moreopenaire +2 more sourcesDistinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients [PDF]
Annals of Translational Medicine, 2021 Although immunotherapy has demonstrated similar clinical activities in the treatment of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC), several studies have shown programmed death-ligand 1 (PD-L1) to have different predictive roles in ADC and SCC.Wang, Shuo, Qu, Xiujuan, Li, Zhi, Che, Xiaofang, Cao, Lili, Yang, Xianghong, Hu, Xuejun, Xu, Ling, Hou, Kezuo, Fan, Yibo, Wen, Ti, Liu, Yunpeng +11 moreopenaire +2 more sourcesPD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
Frontiers in Immunology, 2021 BackgroundThe PD-1/PD-L1 axis has recently emerged as an immune checkpoint that controls antitumor immune responses also in hematological malignancies. However, the use of anti-PD-L1/PD-1 antibodies in multiple myeloma (MM) patients still remains debated,Federica Costa, Rosanna Vescovini, Valentina Marchica, Paola Storti, Laura Notarfranchi, Laura Notarfranchi, Benedetta Dalla Palma, Benedetta Dalla Palma, Denise Toscani, Jessica Burroughs-Garcia, Maria Teresa Catarozzo, Gabriella Sammarelli, Nicola Giuliani, Nicola Giuliani +13 moredoaj +1 more sourceRegulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing–remitting multiple sclerosis
Brain Communications, 2023 Abstract The programmed cell death protein 1/programmed cell death ligand 1 axis plays an important role in the adaptive immune system and has influence on neoplastic and inflammatory diseases, while its role in multiple sclerosis is unclear.Thanos Tsaktanis, Mathias Linnerbauer, Lena Lößlein, Daniel Farrenkopf, Oliver Vandrey, Anne Peter, Ana Cirac, Tobias Beyer, Lucy Nirschl, Verena Grummel, Mark Mühlau, Matthias Bussas, Bernhard Hemmer, Francisco J Quintana, Veit Rothhammer +14 moreopenaire +4 more sourcesPrognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors
Journal of Cancer Research and Therapeutics, 2021 Purpose: The purpose of our meta-analysis is to clarify whether the biomarker of programmed cell death ligand-1 (PD-L1) could predict the treatment efficacy and prognosis of programmed cell death protein-1 (PD-1)/PD-L1 immune-checkpoint inhibitors (ICIs) in head and neck cancer (HNC) patients ...Zilu, Huang, Shuohan, Zheng, Shirong, Ding, Yinghong, Wei, Chen, Chen, Xing, Liu, He, Li, Yunfei, Xia +7 moreopenaire +2 more sourcesEssential versus accessory aspects of cell death: recommendations of the NCCD 2015 [PDF]
, 2014 Cells exposed to extreme physicochemical or mechanical stimuli die in an uncontrollable manner, as a result of their immediate structural breakdown. Such an unavoidable variant of cellular demise is generally referred to as ‘accidental cell death’ (ACD). A Ciechanover, A Criollo, A Degterev, A Degterev, A Degterev, A Gross, A Hochreiter-Hufford, A Kaczmarek, A Linkermann, A Linkermann, A Linkermann, A Linkermann, A Nagasaka, A Oberst, A Oberst, A Pogrebniak, A Rebbaa, A Strasser, A Villunger, AA Fatokun, AA Mailleux, AC Schinzel, AD Dam, AG Fraser, AJ Schile, AM Chinnaiyan, AM Chinnaiyan, AM Choi, AM Verhagen, AU Lindner, AV Vaseva, B D Dynlacht, B Joseph, B La Scola, B La Scola, B Levine, B R Stockwell, B Zhivotovsky, B Zhivotovsky, BA Gibson, BB Wolf, BH Han, C Borner, C Brenner, C Brenner, C Brenner, C Brenner, C Du, C Garrido, C Garrido, C López-Otín, C M Rodrigues, C Munoz-Pinedo, C Muñoz-Pinedo, C Scaffidi, C Scheller, C Volbracht, C Volbracht, CM Haynes, CO Bellamy, CP Baines, CP Baines, CP Dillon, D Adam, D Andrews, D C Rubinsztein, D Chandra, D Denton, D Denton, D Denton, D Denton, D Denton, D E Bredesen, D Grander, D J Klionsky, D R Green, D Raoult, D Ren, D Vercammen, D Vercammen, D Vercammen, D Xue, D Zhu, DA Fruman, DC Rubinsztein, DE Bredesen, DJ Klionsky, DL Berry, DL Vaux, DM Moujalled, DM Moujalled, DM Underhill, DR Green, DR Green, DV Krysko, DV Krysko, DW Zhang, E Basso, E Candi, E F Wagner, E H Baehrecke, E H Cheng, E Laane, E Lugli, E Murphy, E Noch, E S Alnemri, E Tasdemir, E White, E White, EA Minina, EA Slee, EA Slee, EH Baehrecke, EJ Park, F Basit, F Cecconi, F Cecconi, F Gonzalvez, F K Chan, F Madeo, F Pietrocola, F Verrier, FC Kischkel, FH Igney, G A Rabinovich, G Denecker, G Hajnoczky, G Kroemer, G Kroemer, G Kroemer, G Kroemer, G Kroemer, G Kroemer, G Kroemer, G Lettre, G M Fimia, G Marino, G Melino, G Nuñez, G Szabadkai, G Trichonas, G Van Loo, GP Sims, H Gronemeyer, H Ichijo, H Kanuka, H Kenis, H Khalil, H Kim, H L Tang, H Pearson, H Puthalakath, H Puthalakath, H Puthalakath, H Varma, H Wajant, H Walczak, H Walczak, H Wang, H Yoshida, H Zhu, H Zou, H-U Simon, HI Roach, HL Tang, HL Tang, I Amelio, I Martinou, I Vitale, IK Poon, IP Nezis, J A Cidlowski, J E Chipuk, J H Prehn, J Hitomi, J J Lemasters, J Li, J M Abrams, J M Bravo-San Pedro, J M Hardwick, J M Penninger, J Michels, J P Medema, J Sosna, J Wu, J Yang, J Yuan, J Yuan, J Zhao, J-C Marine, J-C Martinou, JA Rickard, JC Reed, JE Chipuk, JE Chipuk, JE Vince, JF Kerr, JG Albeck, JG Albeck, JH Shin, JJ Lemasters, JL Luo, JM Hardwick, JM Murphy, JS Long, JU Schweichel, JW Upton, K Bianchi, K Blomgren, K Kehe, K Kuida, K Kuida, K Miyazaki, K Newton, K Nihira, K Prabhakaran, K Richter, K S Ravichandran, K Segawa, K Tracy, K-M Debatin, KA Spriggs, KC Zimmermann, KN Alavian, KR Knight, L Altucci, L Duprez, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Galluzzi, L Mondragon, L Steinhart, L Sun, L Zitvogel, LC Gomes, M Ankarcrona, M Annicchiarico-Petruzzelli, M Arundine, M Bonora, M Campanella, M Campanella, M Chautan, M D'Amelio, M E Peter, M Elgendy, M Endres, M Irmler, M J Bertrand, M Leist, M Los, M MacFarlane, M Mediavilla-Varela, M Muzio, M O Hengartner, M Okada, M Overholtzer, M Piacentini, M V Blagosklonny, M Woo, M-L Gougeon, MA Burguillos, MA Hughes, MA Mellen, MA Mellen, MA O'Donnell, MB Jensen, MC Wei, ME Peter, MJ Bertrand, ML Coleman, N Di Daniele, N G Bazan, N Holler, N Honarpour, N Mizushima, N Mizushima, N S Chandel, N Tavernarakis, N Vanlangenakker, N Vanlangenakker, N Vanlangenakker, NJ Curtin, NJ McCarthy, NN Danial, O Kepp, O Kepp, O Krysko, P Bouillet, P Golstein, P J Jost, P Kraft, P Li, P Mazzarello, P Meier, P Nicotera, P Nicotera, P Pacher, P Pinton, P Saikumar, P Schotte, P Vandenabeele, P Vandenabeele, P Vandenabeele, P Vandenabeele, PE Czabotar, PG Clarke, PJ Jost, PS Brookes, Q Remijsen, Q Zhang, R A Flavell, R A Knight, R A Lockshin, R De Maria, R Hakem, R Rashmi, R Rizzuto, R Skouta, R Weinlich, RA Lockshin, RA Lockshin, RC Taylor, RJ O'Brien, RM del Moral, RU Janicke, RW Oppenheim, S A Aaronson, S A Lipton, S Barut, S Bhattacharyya, S Dolma, S Enzenmuller, S Fulda, S Fulda, S Grootjans, S He, S J Martin, S Jouan-Lanhouet, S Kumar, S Kumar, S Melino, S Morioka, S Renolleau, S Tan, S Vallabhapurapu, S W Tait, S Zelenay, SA Lakhani, SA Susin, SB Bratton, SC Chow, SJ Dixon, SJ Dixon, SJ Kim, SJ Martin, SJ Martin, SM Knoblach, SM Laster, SM Srinivasula, SN Willis, SW Tait, SW Tait, SW Tait, SW Tait, SW Tait, SW Yu, SW Yu, SY Chen, T Hirsch, T Ide, T Kaufmann, T Lindsten, T M Dawson, T Nakagawa, T Nakamura, T Panaretakis, T Rudel, T Tenev, T Vanden Berghe, T Vanden Berghe, T Vanden Berghe, T Vanden Berghe, T Vanden Berghe, TG Cotter, TJ Daish, TJ Fan, TM Caserta, U Moll, V De Laurenzi, V Giorgio, V Gogvadze, V L Dawson, V Labi, V M Dixit, V Nikoletopoulou, W Fiers, W G Wood, W Han, W Han, W Hou, W Malorni, W S El-Deiry, W Zhang, WJ Kaiser, WJ Kaiser, WS Yang, WW Chen, X Chen, X Li, X Liu, X Luo, X Pan, XM Yin, Y Ben-Neriah, Y Dondelinger, Y Dondelinger, Y Eguchi, Y Fuchs, Y Li, Y Liu, Y Rong, Y Shi, Y Tsujimoto, Y Wang, Y Zaltsman, YP Ow, YS Cho, Z Cai, Z Song, Z Wang, Z Zakeri, ZA Dunai +438 morecore +23 more sourcesCurrent Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
JTO Clinical and Research Reports, 2021 Introduction: The clinical successes seen with anti–programmed cell death protein 1/programmed death-ligand 1 (anti–PD-[L]1) agents have galvanized the field of immuno-oncology.Samuel A. Kareff, MD, MPH, Suraj Samtani, MD, Mauricio Burotto, MD, MSc, Vinay Prasad, MD, MPH, Chul Kim, MD, MPH +4 moredoaj +1 more sourceM2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s [PDF]
, 2019 Background
Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single agents have a lack of ...Dang, Nanmao, Gao, Fei, Huang, Dong, Huang, Jun-Yong, Jowsey, Paul, Li, Jianquan, Lightowlers, Robert N., Martinez-Lopez, Nuria +7 morecore +1 more sourceProgrammed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
Cureus, 2023 The advent of immune checkpoint inhibitors has revolutionized cancer therapy by leveraging the body's immune system to combat malignancies effectively. Among these groundbreaking agents, programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have emerged as pivotal therapeutic approaches.Abaza, Abdelrahman, Sid Idris, Faten, Anis Shaikh, Humna, Vahora, Ilma, Moparthi, Kiran Prasad, Al Rushaidi, Majdah T, Muddam, Meghana Reddy, Obajeun, Omobolanle A, Jaramillo, Arturo P, Khan, Safeera +9 moreopenaire +2 more sources
